Shares of biopharmaceutical company MorphoSys dipped after it successfully raised €102.7 million ($111.7 million) in a capital increase. The funds will be used to fast-track the launch of a myelofibrosis drug and support the clinical development of important pipeline programs.

At 1145 GMT on Thursday, MorphoSys shares experienced a 5% decline, currently priced at EUR33.21. However, the stock is still up 34% since last week following the release of positive clinical-trial data for their investigational drug, pelabresib, on Monday.

As part of the capital increase, MorphoSys issued 3.4 million new shares at a price of EUR30 each, which represents a 14% discount compared to Wednesday's closing price of EUR34.96.

A late-stage clinical trial demonstrated that pelabresib, when combined with ruxolitinib, provided significant benefits compared to the placebo and ruxolitinib alone for patients with myelofibrosis, a form of bone marrow cancer. Ruxolitinib is currently the standard of care for this condition.

In addition to preparing for the launch of pelabresib as a first-line treatment for myelofibrosis, MorphoSys aims to advance their key pipeline programs towards regulatory approval and strengthen their financial position.

Asia-Pacific Stocks Mostly Climb

Intel Unveils New PC Chips for Artificial Intelligence Tasks

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Nemetschek Reports Decrease in Q2 Net Profit
News

Nemetschek Reports Decrease in Q2 Net Profit

Shares of Nemetschek dropped after reporting lower net profit in Q2 due to transition to subscription model. Revenue inc...

Alphabet Inc. Cl A Shares Rally on Positive Trading Session
News

Alphabet Inc. Cl A Shares Rally on Positive Trading Session

Shares of Alphabet Inc. Cl A experienced a remarkable rally, outperforming its competitors in the stock market.

Storms and Their Impact on Older Americans
News

Storms and Their Impact on Older Americans

Storms can have a devastating impact on older Americans, affecting their homes, finances, and health. Discover strategie...

NN Group Reports Rise in Operating Result for First Half of 2023
News

NN Group Reports Rise in Operating Result for First Half of 2023

NN Group has reported a strong rise in operating result for the first half of 2023, exceeding expectations. However, net...